|4.16||-0.2000||-4.59%||Vol 1.29M||1Y Perf 31.19%|
|Oct 30th, 2020 16:00 DELAYED|
|- -%||- -%|
|Target Price||4.43||Analyst Rating||Hold 2.78|
|Potential %||6.49||Finscreener Ranking||★+ 44.20|
|Insiders Trans % 3/6/12 mo.||-/100/100||Value Ranking||★★ 47.55|
|Insiders Value % 3/6/12 mo.||-/100/100||Growth Ranking||★ 34.44|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/100||Income Ranking||— -|
|Market Cap||1.25B||Earnings Rating||Buy|
|Price Range Ratio 52W %||51.92||Earnings Date||6th Nov 2020|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Nov 2020|
|Estimated EPS Next Report||0.12|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.38M|
|Avg. Monthly Volume||1.30M|
|Avg. Quarterly Volume||1.16M|
Amneal Pharmaceuticals Inc. Class A (NYSE: AMRX) stock closed at 4.16 per share at the end of the most recent trading day (a -4.59% change compared to the prior day closing price) with a volume of 1.29M shares and market capitalization of 1.25B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 6000 people. Amneal Pharmaceuticals Inc. Class A CEO is Chintu Patel / Chirag Patel.
The one-year performance of Amneal Pharmaceuticals Inc. Class A stock is 31.19%, while year-to-date (YTD) performance is -13.69%. AMRX stock has a five-year performance of -87.99%. Its 52-week range is between 2.4 and 5.79, which gives AMRX stock a 52-week price range ratio of 51.92%
Amneal Pharmaceuticals Inc. Class A currently has a PE ratio of -, a price-to-book (PB) ratio of 2.51, a price-to-sale (PS) ratio of 0.56, a price to cashflow ratio of 2.30, a PEG ratio of 2.32, a ROA of -4.70%, a ROC of -2.42% and a ROE of -51.11%. The company’s profit margin is 3.66%, its EBITDA margin is 19.70%, and its revenue ttm is $1.36 Billion , which makes it $9.22 revenue per share.
Of the last four earnings reports from Amneal Pharmaceuticals Inc. Class A, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.12 for the next earnings report. Amneal Pharmaceuticals Inc. Class A’s next earnings report date is 06th Nov 2020.
The consensus rating of Wall Street analysts for Amneal Pharmaceuticals Inc. Class A is Hold (2.78), with a target price of $4.43, which is +6.49% compared to the current price. The earnings rating for Amneal Pharmaceuticals Inc. Class A stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amneal Pharmaceuticals Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amneal Pharmaceuticals Inc. Class A has a Sell technical analysis rating based on Technical Indicators (ADX : 29.23, ATR14 : 0.29, CCI20 : -109.85, Chaikin Money Flow : -0.24, MACD : 0.07, Money Flow Index : 46.82, ROC : -17.46, RSI : 38.04, STOCH (14,3) : 0.74, STOCH RSI : 0.00, UO : 28.32, Williams %R : -99.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amneal Pharmaceuticals Inc. Class A in the last 12-months were: Andrew S. Boyer (Option Excercise at a value of $0), Boyer S Andrew (Option Excercise at a value of $0), Chintu Patel (Buy at a value of $2 567 884), Chintu Patel (Option Excercise at a value of $0), Chirag Patel (Buy at a value of $2 567 916), Chirag Patel (Option Excercise at a value of $0), David A. Buchen (Option Excercise at a value of $0), Emily Peterson Alva (Option Excercise at a value of $0), Gautam Patel (Buy at a value of $589 073), Gautam Patel (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), Jeffrey P. George (Buy at a value of $99 050), John J. Kiely (Buy at a value of $44 000), Joseph Todisco (Buy at a value of $144 800), Joseph Todisco (Option Excercise at a value of $0), Nikita Shah (Option Excercise at a value of $0), Paul M. Meister (Buy at a value of $970 344), Paul M. Meister (Option Excercise at a value of $0), Peter R. Terreri (Option Excercise at a value of $0), Ted C. Nark (Option Excercise at a value of $0), Todd P. Branning (Option Excercise at a value of $0)
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.